Evidence map›Paper›PMID 39541539›Full record

ArticleNeuropsychology2025

Affliction class moderates the dementing impact of adipokines.

Donald R Royall, Raymond F Palmer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Donald R RoyallDepartment of Psychiatry, University of Texas Health Science Center.ORCID 0000-0001-6475-0300
Raymond F PalmerDepartment of Family and Community Medicine, University of Texas Health Science Center.

Funding

Novel Methods for Clinical Trials in Dementia and Cognitive DeclineR01AG080548 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI DONALD R ROYALL · 2023 to 2026
$1.4M
National Institutes of Health; National Institute on AgingNIA NIH HHS R01 AG080548University of Texas Health Sceince Center at San Antonio
6 · The paper itself

Abstract

objectiveBiomarker-specific interventions (e.g., for dementia) will necessitate an individualized approach to treatment. We have constructed a psychometric classifier to identify persons adversely impacted by plasma adipokines.

methodThe subjects (

resultsSeven hundred four out of the 1,737 subjects (40.53%) were assigned to the afflicted class. The afflicted subjects had greater dementia severity, lower (adverse)

conclusionsOur approach could guide precision interventions against specific biomarkers. This classifier could be administered by telephone, making class assignment feasible without direct patient contact or biomarker assessment. (PsycInfo Database Record (c) 2025 APA, all rights reserved).

Indexed as

AdipokinesAlzheimer DiseaseBiomarkersAgedAged, 80 and overDementiaFemaleHumansMalePsychometricsAdipokinesBiomarkers

Identifiers

PMID39541539
PMCPMC12329775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.